Tenascin-C induces migration and invasion through JNK/c-Jun signalling in pancreatic cancer

Citations Over TimeTop 10% of 2017 papers

Abstract

Tenascin-C (TNC), a large extracellular matrix glycoprotein, has been reported to be associated with metastasis and poor prognosis in pancreatic cancer. However, the effects and mechanisms of TNC in pancreatic cancer metastasis largely remain unclear. We performed Transwell assays to investigate the effects of TNC on Capan-2, AsPC-1 and PANC-1 cells. In addition, western blot and RT-qPCR assays were used to examine potential TNC metastasis-associated targets, such as JNK/c-Jun, Paxillin/FAK, E-cadherin, N-cadherin, Vimentin, and MMP9/2. Lastly, we utilized a variety of methods, such as immunofluorescence, gelatin zymography and immunoprecipitation, to determine the molecular mechanisms of TNC in pancreatic cancer cell motility. The present study showed that TNC induced migration and invasion in pancreatic cancer cells and regulated a number of metastasis-associated proteins, including the EMT markers, MMP9 and Paxillin. Moreover, our data showed that TNC induced pancreatic cancer cells to generate an EMT phenotype and acquire motility potential through the activation of JNK/c-Jun signalling. In addition, TNC increased the DNA binding activity of c-Jun to the MMP9 promoter, an action likely resulting in increased MMP9 expression and activity. TNC/JNK also markedly induced the phosphorylation of Paxillin on serine 178, which is critical for the association between FAK and Paxillin and promoted the formation of focal adhesions. TNC/JNK initiates cell migration and invasion of pancreatic cancer cells through the promotion of EMT, the transactivation of MMP9 and the phosphorylation of Paxillin on serine 178. TNC may be a potential therapeutic target for treating pancreatic cancer metastasis.

Related Papers

• The expression of MMP_2 and MMP_9 in endometrial carcinoma(2004)
• Determination of Matrix Metalloproteinase2 9 in Cultured Endometriotic Stromal Cells(2011)
• Comparative study of the expression of MMP2 and MMP9 in HepG2 cells and HCC tissues(2010)
• Recombinant Polypeptide CH50 of Fibronectin Inhibits the Expression and Activation of Matrix Metalloproteinase 2 and 9 in Melanoma(2007)
• The Expression of MMP2, MMP9, Type IV Collagen and E - CD in Bladder Transitional Cell Carcinoma and Its Clinical Significance(2003)